To compare the cost-effectiveness of fixed dose combination of solifenacin 6 mg and tamsulosin 0.4 mg in a controlled absorption system (TOCAS) with free dose combination of tolterodine plus tamsulosin, when used for the treatment of patients with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) who do not respond adequately to monotherapy. The analysis was conducted from the perspective of the Spanish National Health System.
A Markov model was developed in Excel, with 1-year time horizon. The transition probabilities of the model were obtained from the NEPTUNE clinical trial and published literature. Unit costs were obtained from Spanish sources. The use of healthcare resources was validated by Spanish clinical experts. Both deterministic and probabilistic analyses were performed to determine the key drivers of the model.
Treatment with fixed dose combination of solifenacin plus TOCAS was found to be dominant, as it resulted in lower annual costs (€ 1,349 vs. € 1,619) and greater quality-adjusted life years (QALY) gained per patient (0.8406 vs. 0.8386) when compared with free dose combination of tolterodine plus tamsulosin. According to the probabilistic analyses, the probability of the fixed dose combination treatment being cost-effective at a willingness to pay threshold of € 20,000 or 30,000 would be 100%.
This analysis suggests that fixed dose combination of solifenacin plus TOCAS represents a cost-effective choice for the treatment of patients with moderate to severe LUTS/BHP, compared to free dose combination of tolterodine plus tamsulosin.
Archivos espanoles de urologia. 2018 Sep [Epub]
Antonio Alcántara, José Manuel Cózar, Carlos Errando, Darío Rubio-Rodríguez, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Ana M Mora, Aurea Duran
Centro de Salud José María Álvarez. Don Benito. Badajoz. España., Hospital Universitario Virgen de las Nieves. Granada. España., Fundación Puigvert. Barcelona. España., Health Value. Madrid. España., Astellas Pharma. Madrid. España., Astellas Pharma Europe Ltd. Chertsey. Reino Unido.